Low-dose ionizing radiation-induced RET/PTC1 rearrangement via the non-homologous end joining pathway to drive thyroid cancer

Abstract

Thyroid cancer incidence increases worldwide annually, primarily due to factors such as ionizing radiation (IR), iodine intake, and genetics. Papillary carcinoma of the thyroid (PTC) accounts for about 80% of thyroid cancer cases. RET/PTC1 (coiled-coil domain containing 6 [CCDC6]-rearranged during transfection) rearrangement is a distinctive feature in over 70% of thyroid cancers who exposed to low doses of IR in Chernobyl and Hiroshima–Nagasaki atomic bombings. This study aims to elucidate mechanism between RET/PTC1 rearrangement and IR in PTC. N-thy-ori-3-1 cells were subjected to varying doses of IR (2/1/0.5/0.2/0.1/0.05 Gy) of IR at different days, and result showed low-dose IR-induced RET/PTC1 rearrangement in a dose-dependent manner. RET/PTC1 has been observed to promote PTC both in vivo and in vitro. To delineate the role of different DNA repair pathways, SCR7, RI-1, and Olaparib were employed to inhibit non-homologous end joining (NHEJ), homologous recombination (HR), and microhomology-mediated end joining (MMEJ), respectively. Notably, inhibiting NHEJ enhanced HR repair efficiency and reduced IR-induced RET/PTC1 rearrangement. Conversely, inhibiting HR increased NHEJ repair efficiency and subsequent RET/PTC1 rearrangement. The MMEJ did not show a markable role in this progress. Additionally, inhibiting DNA-dependent protein kinase catalytic subunit (DNA-PKcs) decreased the efficiency of NHEJ and thus reduced IR-induced RET/PTC1 rearrangement. To conclude, the data suggest that NHEJ, rather than HR or MMEJ, is the critical cause of IR-induced RET/PTC1 rearrangement. Targeting DNA-PKcs to inhibit the NHEJ has emerged as a promising therapeutic strategy for addressing IR-induced RET/PTC1 rearrangement in PTC.

Keywords

DNA-PKcs / low-dose ionizing radiation / NHEJ / RET/PTC1 rearrangement / thyroid cancer

References

[1] Albi E, Cataldi S, Lazzarini A, et al. Radiation and thyroid cancer. Int J Mol Sci. 2017; 18(5): 911.

[2] Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016; 388(10061): 2783-2795.

[3] Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014; 65: 125-137.

[4] Virginia AL. Papillary thyroid carcinoma: an update. Mod Pathol. 2011; 24(suppl 2): S1-S9.

[5] Pacini F, Vorontsova T, Demidchik EP, et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab. 1997; 82(11): 4367.

[6] Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab. 2001; 86(7): 3211-3216.

[7] Robbins J, Schneider AB. Thyroid cancer following exposure to radioactive iodine. Rev Endocr Metab Disord. 2000; 1(3): 197-203.

[8] Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013; 123(11): 4935-4944.

[9] Ashwini BR, Nirmala C, Natarajan M, Biligi DS. A study to evaluate association of nuclear grooving in benign thyroid lesions with RET/PTC1 and RET/PTC3 gene translocation. Thyroid Res. 2023; 16(1): 21.

[10] Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002; 13(1): 3-16.

[11] Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001; 8(6): 345-354.

[12] Burssed B, Zamariolli M, Bellucco FT, Melaragno MI. Mechanisms of structural chromosomal rearrangement formation. Mol Cytogenet. 2022; 15(1): 23.

[13] Carvalho CM, Lupski JR. Mechanisms underlying structural variant formation in genomic disorders. Nat Rev Genet. 2016; 17(4): 224-238.

[14] Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab. 2005; 90(4): 2364-2369.

[15] Ottaviani D, LeCain M, Sheer D. The role of microhomology in genomic structural variation. Trends Genet. 2014; 30(3): 85-94.

[16] Hattori A, Fukami M. Established and novel mechanisms leading to de novo genomic rearrangements in the human germline. Cytogenet Genome Res. 2020; 160(4): 167-176.

[17] Wray J, Williamson EA, Singh SB, et al. PARP1 is required for chromosomal translocations. Blood. 2013; 121(21): 4359-4365.

[18] Soni A, Siemann M, Grabos M, Murmann T, Pantelias GE, Iliakis G. Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res. 2014; 42(10): 6380-6392.

[19] Ahrabi S, Sarkar S, Pfister SX, et al. A role for human homologous recombination factors in suppressing microhomology-mediated end joining. Nucleic Acids Res. 2016; 44(12): 5743-5757.

[20] Gu W, Zhang F, Lupski JR. Mechanisms for human genomic rearrangements. PathoGenetics. 2008; 1(1): 4.

[21] Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020; 5(1): 60.

[22] Fang X, Huang Z, Zhai K, et al. Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice. Sci Transl Med. 2021; 13(600): eabc7275.

[23] Gerlach BD, Ampomah PB, Yurdagul A Jr, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 2021; 33(12): 2445-2463. e8.

[24] Gao SS, Guan H, Yan S, et al. TIP60 K430 SUMOylation attenuates its interaction with DNA-PKcs in S-phase cells: facilitating homologous recombination and emerging target for cancer therapy. Sci Adv. 2020; 6(28): eaba7822.

[25] Xie Y, Liu YK, Guo ZP, et al. RBX1 prompts degradation of EXO1 to limit the homologous recombination pathway of DNA double-strand break repair in G1 phase. Cell Death Differ. 2020; 27(4): 1383-1397.

[26] van Gerwen M, Alerte E, Alsen M, Little C, Sinclair C, Genden E. The role of heavy metals in thyroid cancer: a meta-analysis. J Trace Elem Med Biol. 2021; 69: 126900.

[27] Shkala K, Zhenyu Z, Whitney S, et al. Ambient particulate matter air pollution is associated with increased risk of papillary thyroid cancer. Surgery. 2021; 171(1): 212-219.

[28] Gore AC, Chappell VA, Fenton SE, et al. EDC-2: the endocrine society’s second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015; 36(6): E1-E150.

[29] Yu-Jin K, Hye-Sun L, Sang-Wook K, Ji-Won L. Association between consumption of iodine-rich foods and thyroid cancer prevalence: findings from a large population-based study. Nutrients. 2024; 16(7): 1041.

[30] Hoskins SB, Torgerson L. Synchronous papillary thyroid cancer and colorectal cancer in a young patient with a CHEK2 mutation. Case Rep Oncol. 2024; 17(1): 524-531.

[31] Richardson DB. Exposure to ionizing radiation in adulthood and thyroid cancer incidence. Epidemiology. 2009; 20(2): 181-187.

[32] Kitahara CM, Preston DL, Neta G, et al. Occupational radiation exposure and thyroid cancer incidence in a cohort of U.S. radiologic technologists, 1983–2013. Int J Cancer. 2018; 143(9): 2145-2149.

[33] Lin Y, Wu Y. Trends in incidence and overdiagnosis of thyroid cancer in China, Japan, and South Korea. Cancer Sci. 2023; 114(10): 4052-4062.

[34] Li M, Zheng R, Dal Maso L, Zhang S, Wei W, Vaccarella S. Mapping overdiagnosis of thyroid cancer in China. Lancet Diabetes Endocrinol. 2021; 9(6): 330-332.

[35] Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021; 9(4): 225-234.

[36] Mizuno T, Iwamoto KS, Kyoizumi S, et al. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene. 2000; 19(3): 438-443.

[37] Barone MV, Sepe L, Melillo RM, et al. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene. 2001; 20(48): 6973-6982.

[38] Gilbert-Sirieix M, Ripoche H, Malvy C, Massaad-Massade L. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells. Thyroid. 2010; 20(10): 1053-1065.

[39] Cassinelli G, Favini E, Degl’Innocenti D, et al. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia. 2009; 11(1): 10-21.

[40] Ameziane-El-Hassani R, Boufraqech M, Lagente-Chevallier O, et al. Role of H₂O₂ in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res. 2010; 70(10): 4123-4132.

[41] Mitsutake N, Saenko V. Molecular pathogenesis of pediatric thyroid carcinoma. J Radiat Res. 2021; 62: i71-i77.

[42] Allocca C, Cirafici A, Laukkanen M, Castellone M. Serine 897 phosphorylation of EPHA2 is involved in signaling of oncogenic ERK1/2 drivers in thyroid cancer cells. Thyroid. 2021; 31(1): 76-87.

[43] Lehman C, Dillon L, Nikiforov Y, Wang Y. DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements. Carcinogenesis. 2017; 38(3): 293-301.

[44] Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000; 290(5489): 138-141.

[45] Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, Grieco M. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene. 2004; 23(1): 109-121.

[46] Gandhi M, Medvedovic M, Stringer JR, Nikiforov YE. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene. 2006; 25(16): 2360-2366.

[47] Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009; 461(7267): 1071-1078.

[48] Shimizu I, Yoshida Y, Suda M, Minamino T. DNA damage response and metabolic disease. Cell Metab. 2014; 20(6): 967-977.

[49] Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010; 40(2): 179-204.

[50] Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017; 18(8): 495-506.

[51] Zhao B, Rothenberg E, Ramsden DA, Lieber MR. The molecular basis and disease relevance of non-homologous DNA end joining. Nat Rev Mol Cell Biol. 2020; 21(12): 765-781.

[52] Yue X, Bai C, Xie D, Ma T, Zhou PK. DNA-PKcs: a multi-faceted player in DNA damage response. Front Genet. 2020; 11: 607428.

[53] Chen X, Xu X, Chen Y, et al. Structure of an activated DNA-PK and its implications for NHEJ. Mol Cell. 2021; 81(4): 801-810. e3.

[54] Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell. 1993; 72(1): 131-142.

[55] Hartley KO, Gell D, Smith GC, et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell. 1995; 82(5): 849-856.

[56] Baumann P, West SC. DNA end-joining catalyzed by human cell-free extracts. Proc Nat Acad Sci U S A. 1998; 95(24): 14066-14070.

[57] Jackson SP, Jeggo PA. DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Trends Biochem Sci. 1995; 20(10): 412-415.

[58] Zhou H, Du W, Li Y, et al. Effects of melatonin on fatty liver disease: the role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy. J Pineal Res. 2018; 64(1): e12450.

[59] Sirbu BM, Cortez D. DNA damage response: three levels of DNA repair regulation. Cold Spring Harb Perspect Biol. 2013; 5(8): a012724.

[60] Iliakis GE. New players in the regulation of DNA-PK activity: survivin joins the crowd. Cancer Res. 2021; 81(9): 2270-2271.

[61] Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006; 66(10): 5354-5362.

[62] Han Y, Jin F, Xie Y, et al. DNA-PKcs PARylation regulates DNA-PK kinase activity in the DNA damage response. Mol Med Rep. 2019; 20(4): 3609-3616.

[63] Guo Z, Wang S, Xie Y, et al. HUWE1-dependent DNA-PKcs neddylation modulates its autophosphorylation in DNA damage response. Cell Death Dis. 2020; 11(5): 400.

[64] Chen Y, Jiang T, Zhang H, et al. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. Nat Cell Biol. 2020; 22(10): 1276-1285.

[65] Holley A, Xu Y, St Clair D, St Clair W. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann NY Acad Sci. 2010; 1201: 129-136.

[66] Unger K, Zurnadzhy L, Walch A, et al. RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH. Br J Cancer. 2006; 94(10): 1472-1477.

[67] Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997; 15(11): 1263-1273.

[68] Seluanov A, Mao Z, Gorbunova V. Analysis of DNA double-strand break (DSB) repair in mammalian cells. J Vis Exp. 2010; 43: 2002.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.